Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy - PubMed (original) (raw)
. 2000 Mar 2;19(10):1245-56.
doi: 10.1038/sj.onc.1203434.
Affiliations
- PMID: 10713666
- DOI: 10.1038/sj.onc.1203434
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy
A N Bullock et al. Oncogene. 2000.
Abstract
The tumour suppressor p53 is mutated in half of all human cancers, most frequently with missense substitutions in its core domain. We present a new assessment of the mutation database based on quantitative folding and DNA-binding studies of the isolated core domain. Our data identify five distinct mutant classes that correlate with four well-defined regions of the core domain structure. On extrapolation to 37 degrees C the wild-type protein has a stability of 3.0 kcal/mol. This also emerges as an oncogenic threshold: all beta-sandwich mutants destabilized by this amount (50% denatured) are expected to promote cancer. Other weakly destabilizing mutations are restricted to loop 3 in the DNA-binding region. Drugs that stabilize mutant p53 folding have the potential to reactivate apoptotic signalling pathways in tumour cells either by transactivation-dependent or independent pathways. Using an affinity ligand as a proof of principle we have recovered the thermodynamic stability of the hotspot G245S. With reference states for the five mutant classes as a guide, future therapeutic strategies may similarly stabilize partially structured or binding states of mutant p53 that restore limited p53 pathways to tumour suppression.
Similar articles
- Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z. Suad O, et al. J Mol Biol. 2009 Jan 9;385(1):249-65. doi: 10.1016/j.jmb.2008.10.063. Epub 2008 Oct 30. J Mol Biol. 2009. PMID: 18996393 - Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G, Wiman KG. Selivanova G, et al. Oncogene. 2007 Apr 2;26(15):2243-54. doi: 10.1038/sj.onc.1210295. Oncogene. 2007. PMID: 17401433 Review. - Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.
Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR. Rippin TM, et al. Oncogene. 2002 Mar 28;21(14):2119-29. doi: 10.1038/sj.onc.1205362. Oncogene. 2002. PMID: 11948395 - Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A, Rotter V. Sigal A, et al. Cancer Res. 2000 Dec 15;60(24):6788-93. Cancer Res. 2000. PMID: 11156366 Review. - Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
Lubin DJ, Butler JS, Loh SN. Lubin DJ, et al. J Mol Biol. 2010 Jan 29;395(4):705-16. doi: 10.1016/j.jmb.2009.11.013. Epub 2009 Nov 11. J Mol Biol. 2010. PMID: 19913028
Cited by
- Bioinformatic Characterization of the Functional and Structural Effect of Single Nucleotide Mutations in Patients with High-Grade Glioma.
Vélez Gómez S, Martínez Garro JM, Ortiz Gómez LD, Salazar Flórez JE, Monroy FP, Peláez Sánchez RG. Vélez Gómez S, et al. Biomedicines. 2024 Oct 9;12(10):2287. doi: 10.3390/biomedicines12102287. Biomedicines. 2024. PMID: 39457600 Free PMC article. - TP53: the unluckiest of genes?
Joerger AC, Stiewe T, Soussi T. Joerger AC, et al. Cell Death Differ. 2024 Oct 23. doi: 10.1038/s41418-024-01391-6. Online ahead of print. Cell Death Differ. 2024. PMID: 39443700 Review. - Targeting mutant p53: a key player in breast cancer pathogenesis and beyond.
Qayoom H, Haq BU, Sofi S, Jan N, Jan A, Mir MA. Qayoom H, et al. Cell Commun Signal. 2024 Oct 10;22(1):484. doi: 10.1186/s12964-024-01863-9. Cell Commun Signal. 2024. PMID: 39390510 Free PMC article. Review. - Oncogenic p53 triggers amyloid aggregation of p63 and p73 liquid droplets.
Petronilho EC, de Andrade GC, de Sousa GDS, Almeida FP, Mota MF, Gomes AVDS, Pinheiro CHS, da Silva MC, Arruda HRS, Marques MA, Vieira TCRG, de Oliveira GAP, Silva JL. Petronilho EC, et al. Commun Chem. 2024 Sep 16;7(1):207. doi: 10.1038/s42004-024-01289-x. Commun Chem. 2024. PMID: 39284933 Free PMC article. - Functional Investigations of p53 Acetylation Enabled by Heterobifunctional Molecules.
Chen LY, Singha Roy SJ, Jadhav AM, Wang WW, Chen PH, Bishop T, Erb MA, Parker CG. Chen LY, et al. ACS Chem Biol. 2024 Sep 20;19(9):1918-1929. doi: 10.1021/acschembio.4c00438. Epub 2024 Sep 9. ACS Chem Biol. 2024. PMID: 39250704
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous